HAEMONETICS CORP: insider trades · United States · SEC (Form 4)

About HAEMONETICS CORP

Haemonetics Corp. (NYSE: HAE) is a United States–based, publicly listed medical technology company focused on blood collection, plasma processing, and hospital hemostasis management solutions. Founded in 1971, the company has built a long operating history around a core franchise in apheresis and blood-component technologies, then expanded into a broader platform serving plasma centers, blood centers, and hospitals. Its global headquarters is in Boston, Massachusetts, reflecting a recent consolidation of corporate functions in the Boston area. ([haemonetics.com](https://www.haemonetics.com/about-us?utm_source=openai)) Haemonetics’ business model is organized around several complementary product and service lines. On one side, it offers end-to-end plasma collection technologies designed to improve the productivity and operating efficiency of plasma centers. It also supplies products and systems used by blood centers to collect in-demand blood components. On the hospital side, the company markets hemostasis management and transfusion-related solutions, including diagnostic instruments and software that help clinicians assess bleeding and clotting risk, monitor antithrombotic therapy, and manage blood products more efficiently. Key brands include TEG, Haemonetics’ well-known viscoelastic hemostasis testing platform, BloodTrack for hospital blood management, and the VASCADE family for vascular closure. ([haemonetics.com](https://www.haemonetics.com/about-us?utm_source=openai)) From a competitive standpoint, Haemonetics occupies a specialized niche with meaningful technology and workflow barriers. Its value proposition combines capital equipment, consumables, software, and service, which can support sticky customer relationships and recurring revenue characteristics. The company emphasizes innovation across product, software, and market development, supported by clinical, medical, and regulatory capabilities. Over time, it has built an international footprint and describes itself as a global medical technology company serving customers across multiple geographies. ([haemonetics.com](https://www.haemonetics.com/about-us/corporate-responsibility/our-society?utm_source=openai)) Recent developments suggest a portfolio focused on higher-quality growth and margin improvement. In fiscal 2025, management said the company continued to see strong demand for apheresis products in blood centers while divesting its Whole Blood product line, a move intended to better align resources toward higher-margin, higher-growth opportunities. More recently, Haemonetics announced its fourth-quarter and fiscal 2026 financial results on May 7, 2026, and also highlighted participation in the Bank of America 2026 Healthcare Conference. In April 2026, the company disclosed a new study highlighting the safety and efficacy profile of VASCADE MVP XL in large-bore venous access closure procedures, reinforcing the ongoing clinical positioning of its vascular closure franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/313143/000031314325000041/hae-20250605.htm?utm_source=openai))